JP5833626B2 - ラパチニブの調製プロセス及び中間体 - Google Patents
ラパチニブの調製プロセス及び中間体 Download PDFInfo
- Publication number
- JP5833626B2 JP5833626B2 JP2013500311A JP2013500311A JP5833626B2 JP 5833626 B2 JP5833626 B2 JP 5833626B2 JP 2013500311 A JP2013500311 A JP 2013500311A JP 2013500311 A JP2013500311 A JP 2013500311A JP 5833626 B2 JP5833626 B2 JP 5833626B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- lapatinib
- salt
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002136 L01XE07 - Lapatinib Substances 0.000 title claims description 34
- 229960004891 lapatinib Drugs 0.000 title claims description 33
- 238000002360 preparation method Methods 0.000 title claims description 6
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 145
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 80
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 67
- 239000000203 mixture Substances 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 45
- 238000006243 chemical reaction Methods 0.000 claims description 44
- 229960001320 lapatinib ditosylate Drugs 0.000 claims description 44
- AZBFJBJXUQUQLF-UHFFFAOYSA-N n-(1,5-dimethylpyrrolidin-3-yl)pyrrolidine-1-carboxamide Chemical compound C1N(C)C(C)CC1NC(=O)N1CCCC1 AZBFJBJXUQUQLF-UHFFFAOYSA-N 0.000 claims description 41
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 40
- -1 lapatinib ditosylate monohydrate Chemical class 0.000 claims description 37
- 230000008569 process Effects 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 229910052763 palladium Inorganic materials 0.000 claims description 34
- 239000002904 solvent Substances 0.000 claims description 33
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 23
- 229910052751 metal Inorganic materials 0.000 claims description 21
- 239000002184 metal Substances 0.000 claims description 21
- 239000002585 base Substances 0.000 claims description 20
- 239000003054 catalyst Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 17
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 16
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 14
- 229910052723 transition metal Inorganic materials 0.000 claims description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 13
- 239000007795 chemical reaction product Substances 0.000 claims description 12
- 239000003446 ligand Substances 0.000 claims description 12
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 10
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 10
- 239000012320 chlorinating reagent Substances 0.000 claims description 9
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical group [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 9
- 150000003624 transition metals Chemical class 0.000 claims description 9
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 8
- 230000002140 halogenating effect Effects 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 6
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 claims description 6
- 125000002015 acyclic group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 150000002940 palladium Chemical class 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 150000004703 alkoxides Chemical class 0.000 claims description 2
- 150000008064 anhydrides Chemical group 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 229910021645 metal ion Inorganic materials 0.000 claims description 2
- 229910001463 metal phosphate Inorganic materials 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- 150000007942 carboxylates Chemical class 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 14
- 238000005859 coupling reaction Methods 0.000 description 13
- 238000002425 crystallisation Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 230000008025 crystallization Effects 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 229940088679 drug related substance Drugs 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- GASBYYVOUWGWTB-UHFFFAOYSA-N 6-iodo-n-phenylquinazolin-4-amine Chemical class C12=CC(I)=CC=C2N=CN=C1NC1=CC=CC=C1 GASBYYVOUWGWTB-UHFFFAOYSA-N 0.000 description 5
- 229910052783 alkali metal Inorganic materials 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 150000004682 monohydrates Chemical class 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- AYPFEYDGZDPAPE-UHFFFAOYSA-N 3-chloro-4-[(3-fluorophenyl)methoxy]aniline Chemical compound ClC1=CC(N)=CC=C1OCC1=CC=CC(F)=C1 AYPFEYDGZDPAPE-UHFFFAOYSA-N 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 231100000024 genotoxic Toxicity 0.000 description 4
- 230000001738 genotoxic effect Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000006268 reductive amination reaction Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000006880 cross-coupling reaction Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012456 homogeneous solution Substances 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- JUWYQISLQJRRNT-UHFFFAOYSA-N (5-formylfuran-2-yl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)O1 JUWYQISLQJRRNT-UHFFFAOYSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- VQKFNUFAXTZWDK-UHFFFAOYSA-N 2-Methylfuran Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 2
- SDNXQWUJWNTDCC-UHFFFAOYSA-N 2-methylsulfonylethanamine Chemical compound CS(=O)(=O)CCN SDNXQWUJWNTDCC-UHFFFAOYSA-N 0.000 description 2
- AMYYUKGKCJKCBI-UHFFFAOYSA-N 2-methylsulfonylethanamine;hydrochloride Chemical compound Cl.CS(=O)(=O)CCN AMYYUKGKCJKCBI-UHFFFAOYSA-N 0.000 description 2
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- XGKCRFUEZJXUKS-UHFFFAOYSA-N 5-(4-chloroquinazolin-6-yl)furan-2-carbaldehyde;hydrochloride Chemical compound Cl.C1=C2C(Cl)=NC=NC2=CC=C1C1=CC=C(C=O)O1 XGKCRFUEZJXUKS-UHFFFAOYSA-N 0.000 description 2
- PUGXMZKDRVGIHC-UHFFFAOYSA-N 6-iodo-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=CC(I)=CC=C21 PUGXMZKDRVGIHC-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 208000022120 Jeavons syndrome Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000005265 dialkylamine group Chemical group 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- PTXJGGGNGMPMBG-UHFFFAOYSA-N ditert-butyl-[2-(1,3,5-triphenylpyrazol-4-yl)pyrazol-3-yl]phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=NN1C1=C(C=2C=CC=CC=2)N(C=2C=CC=CC=2)N=C1C1=CC=CC=C1 PTXJGGGNGMPMBG-UHFFFAOYSA-N 0.000 description 2
- JAIIBHBCNPAPPF-UHFFFAOYSA-N ditert-butyl-[2-(3,5-diphenylpyrazol-1-yl)phenyl]phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1N1C(C=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 JAIIBHBCNPAPPF-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000010935 polish filtration Methods 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- SANWDQJIWZEKOD-UHFFFAOYSA-N tributyl(furan-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CO1 SANWDQJIWZEKOD-UHFFFAOYSA-N 0.000 description 2
- YZBBUYKPTHDZHF-KNVGNIICSA-N (3R)-7,2'-dihydroxy-4'-methoxyisoflavanol Chemical compound OC1=CC(OC)=CC=C1[C@H]1C(O)C2=CC=C(O)C=C2OC1 YZBBUYKPTHDZHF-KNVGNIICSA-N 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-Bis(diphenylphosphino)propane Substances C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 1
- HCSCWJCZRCSQFA-UHFFFAOYSA-N 1-methylpyrrolidin-2-one;hydrate Chemical compound O.CN1CCCC1=O HCSCWJCZRCSQFA-UHFFFAOYSA-N 0.000 description 1
- XSEWEFIUXYGXCA-UHFFFAOYSA-N 1-methylsulfonylethanamine Chemical compound CC(N)S(C)(=O)=O XSEWEFIUXYGXCA-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- GNENVASJJIUNER-UHFFFAOYSA-N 2,4,6-tricyclohexyloxy-1,3,5,2,4,6-trioxatriborinane Chemical compound C1CCCCC1OB1OB(OC2CCCCC2)OB(OC2CCCCC2)O1 GNENVASJJIUNER-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- BHLAFAUALUGNSA-UHFFFAOYSA-N 5-(4-oxo-1h-quinazolin-6-yl)furan-2-carbaldehyde Chemical compound O1C(C=O)=CC=C1C1=CC=C(N=CNC2=O)C2=C1 BHLAFAUALUGNSA-UHFFFAOYSA-N 0.000 description 1
- SLHOSJCCRNVWFC-UHFFFAOYSA-N 5-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]furan-2-carbaldehyde;hydrochloride Chemical compound Cl.FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(=CC=C4N=CN=3)C=3OC(C=O)=CC=3)=CC=2)Cl)=C1 SLHOSJCCRNVWFC-UHFFFAOYSA-N 0.000 description 1
- MLSBXWZCDMRNIX-UHFFFAOYSA-N 6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]-1h-quinazolin-4-one Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2O)C2=C1 MLSBXWZCDMRNIX-UHFFFAOYSA-N 0.000 description 1
- BLJDQJLSUDXUGL-UHFFFAOYSA-N 6-iodoquinazoline Chemical compound N1=CN=CC2=CC(I)=CC=C21 BLJDQJLSUDXUGL-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- BMIRIQXMBGMBEN-UHFFFAOYSA-N O=C1NC=NC2=CC=C(C=C12)C1=C(OC=C1)C=O Chemical compound O=C1NC=NC2=CC=C(C=C12)C1=C(OC=C1)C=O BMIRIQXMBGMBEN-UHFFFAOYSA-N 0.000 description 1
- BLJZMMCUFGZPAI-UHFFFAOYSA-N O=CC(OC=C1)=C1C(C=C12)=CC=C1N=CN=C2Cl Chemical compound O=CC(OC=C1)=C1C(C=C12)=CC=C1N=CN=C2Cl BLJZMMCUFGZPAI-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- YYHSCZWIVHJCFP-UHFFFAOYSA-N [B]C1=CC=C(C=O)O1 Chemical compound [B]C1=CC=C(C=O)O1 YYHSCZWIVHJCFP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- BRTALTYTFFNPAC-UHFFFAOYSA-N boroxin Chemical compound B1OBOBO1 BRTALTYTFFNPAC-UHFFFAOYSA-N 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- PZJSZBJLOWMDRG-UHFFFAOYSA-N furan-2-ylboronic acid Chemical compound OB(O)C1=CC=CO1 PZJSZBJLOWMDRG-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical group CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 231100000822 oral exposure Toxicity 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000007832 transition metal-catalyzed coupling reaction Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 229940094060 tykerb Drugs 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Description
特許文献2及び特許文献3に開示された従来法と対照的に、本発明は、市販の出発物質の式(Va)(6−ヨードキナゾリン−4(3H)−オン)及び(VIa)(5−ホルミルフラン−2−イルボロン酸)、又は式(V)及び(VI)のこれらの類縁体の使用に基づく式(IX)の化合物を提供する合成経路において、最も川上の段階で遷移金属触媒によるカップリング反応を行った。従って、本発明の1つの態様では、ラパチニブは式(IX)の新規化合物から作られる(スキーム2)。
i)式(IX)の化合物を活性化し、
ii)活性化した式(IX)の化合物と3−クロロ−4−(3−フルオロベンジルオキシ)アニリン((VII))とを溶媒中で塩基存在下又は非存在下で反応させて、式(IV)の化合物又はその塩を製造し、そして、
塩素化剤は、SOCl2、POCl3、(COCl)2、PCl3、PCl5、COCl2などが好ましく、SOCl2又はPOCl3が最も好ましい。これらの塩素化剤を用いるときは、DMF又はDMACなどのアミド、好ましくはDMFを、触媒量加えることが好ましい。これらの塩素化剤を用いるときは、式(Xa)の化合物の塩酸塩((Xa).HCl)を得ることが好ましい。
スルホン化剤は、MsCl、p−TsCl、Tf2Oなどが好ましい。
臭素化剤は、POBr3、PBr3などが好ましい。
i)式(IX)の化合物を2−(メチルスルホニル)エタンアミン((VIII))又はその塩(すなわち(VIII).HCl)と反応させて式(XI)の化合物を製造し、
ii)式(XI)の化合物を活性剤で活性化して式(XII)の化合物を製造し、そして、
iii)式(XII)の化合物と式(VII)の化合物との反応によって、式(XII)の化合物をラパチニブに転化する。
Yは、CH=O、CH(OR)2などであり、
CH(OR)2とB(OR)2は、環状又は非環状であり、
B(OR)2は、ボロン酸無水物(すなわち、ボロキシン、又はボロン酸の環状三量体無水物として知られている。)とすることができ、
Rは、アルキル、アリール、ヘテロアリール、アリルなどであり、
Mは、カリウムを含むアルカリ金属などの金属イオンである。
この反応は、有効量の触媒、塩基、及び溶媒の存在下で行う。
溶媒は、有機溶媒と水で構成されると好ましい。
式(VI)の化合物は、式(VIa)のものであると好ましい。
反応は、60〜95℃の間の温度で行ってもよい。また、この温度は、約80℃であってもよい。
実施例1: 5−(4−オキソ−3,4−ジヒドロキナゾリン−6−イル)フラン−2−カルバルデヒド(IX)の合成
式(Xa)の化合物: 1H NMR(300MHz,d6−DMSO):δ 7.53(d,J=3.3Hz,1H)、7.68(d,J=3.3Hz,1H)、8.02(d,J=8.7Hz,1H)、8.42(d,J=8.4Hz,1H)、8.54(d,J=2.1Hz,1H)、8.90(s,1H)、9.64(s,1H); 13C NMR(75MHz、CDCl3):δ 111.5、122.8、122.9、123.7、125.9、129.1、132.5、142.1、149.3、152.9、156.6、159.7、179.1
式(IV)の化合物 1H NMR(300MHz,d6−DMSO): δ 5.28(s,2H)、7.19(td,J=8.7Hz,J=2.1Hz 1H)、7.34(m,4H)、7.43(d,J=3.6Hz,1H)、7.49(m,1H)、7.73(dd,J=8.7Hz J=2.7Hz,1H)、7.76(d,J=3.6Hz,1H)、7.88(d,J=9Hz,1H)、8.07(d,J=2.1Hz,1H)、8.32(dd,J=4.43Hz,J=1.95Hz,1H)、8.95(d,J=1.5Hz,1H)、9.68(s,1H)。
ラパチニブ: 1H NMR(300MHz,d6−DMSO): δ 2.98(t,J=6.75Hz,1H)、3.04(s,1H)、3.29(t,J=6.6Hz,1H)、3.83(s,1H)、5.28(s,1H)、6.50(d,J=3.0Hz,1H)、7.08(d,J=3.3Hz,1H)、7.20(m,1H)、7.33(m,4H)、7.48(m,1H)、7.76(m,1H)、7.80(d,J=9Hz,1H)、8.04(d,J=2.75Hz,1H)、8.17(dd,J=8.7Hz,J=1.8Hz,1H)、8.56(s,1H)、8.75(d,J=1.8Hz,1H)。
ラパチニブジトシレート(5.0g、5.4mmol、個々の不純物の最大値0.8%のHPLC純度96.5%)を70℃(内部温度)でDMSO(10ml)に溶解した。70〜80℃(内部温度)でMeCN(10ml)を混合物中に滴下し、この温度で1時間攪拌した。4時間かけて混合物を室温に冷却した。MeCN(30ml)を滴下し、混合物を1時間攪拌し、次いで濾過し、MeCN(10ml)で洗浄した。濾過ケーキを真空下60℃で16時間乾燥して、HPLC純度99.6%、HPLC収率78%で、(特許文献3で開示されたような)結晶形態1としてラパチニブジトシレート4.0gを得た。
ラパチニブジトシレート(3g、3.25mmol、HPLC純度99.3%)をDMF(18ml)に80℃で溶解し、1時間攪拌した。混合物を熱濾過した。濾液にMeCN(18ml)を80℃で加えた。温度を70℃に下げ、結晶が沈殿した。混合物を70℃で1時間保ち、次いで60℃で1時間保った。混合物を更に0℃に冷却し、2時間攪拌した。ラパチニブジトシレートの結晶を濾過で単離し、真空下40℃で一晩乾燥した。HPLC純度99.9%のラパチニブジトシレート(2.5g、2.70mmol、収率83%)を得た。XRPD分析(図9)は、これが特許文献5で開示されるような形態2であることを示した。
ラパチニブジトシレート(2.0g、HPLC純度96.7%、2.1mmol)を80℃(内部温度)でDMSO(5ml)に溶解し、ラパチニブジトシレートが溶解したままで溶液を濾過した。次いで、MeCN(5ml、2.5P)と水(0.3ml)の混合物を濾過した溶液に70〜80℃(内部温度)で滴下した。混合物を10℃/hの割合で60℃まで冷却し、60℃に2時間保ち、次いでゆっくり50℃に冷却した。50℃で1時間保った後に、MeCN(15ml)を加え、次に混合物を20〜30℃に冷却し、20〜30℃で2時間攪拌した。スラリーを濾過し、MeCN(6ml)で洗浄し、そして濾過ケーキを真空下60℃で4時間乾燥して、ラパチニブジトシレート一水和物(1.7g、純度99.4面積%、1.8mmol)を得た。XRPD分析(図10)は、これが特許文献3で開示されるような一水和物結晶形態であることを示した。
式(XI)の化合物(0.4g、1.15mmol)のトルエン(10ml)懸濁液に、POCl3(0.21g、1.38mmol)を加え、続いてEt3N(0.14g、1.38mmol)を加えた。90℃で2時間攪拌した後、混合物を周囲温度まで冷却し、MEK(20ml)中の式(VII)の化合物(0.6g、2.39mmol)を加えた。混合物を90℃で2時間攪拌し、周囲温度まで冷却し、1N水酸化ナトリウム水溶液(20ml)とTHFを加えた。水相を分離し、THFで二度抽出した(各20ml)。合わせたTHF相を濃縮して0.8gの粗生産物を得、それをカラムクロマトグラフィー(3%MeOHのDCMで展開)で精製してHPLC純度59%のラパチニブ(10mg、0.01mmol)を得た。
反応が完了するまで(TLC分析)、式(IX)の化合物(0.6g、2.5mmol)、SOCl2(15ml)、及びDMF1滴の混合物を還流下加熱した。揮発成分(SOCl2を含む)を減圧留去して、次工程に直接用いることができる粗(Xa).HCl(0.9g)得た。
HPLC分析が反応完了を示すまで、(Xa).HCl(1.0g、2.7mmol)と3−クロロ−4−(3−フルオロベンジルオキシ)アニリン((VII);0.85g、3.4mmol)のTHF(20ml)混合物を60℃で加熱した。混合物を約25℃に冷却し、2.8NのNaOH水溶液(5ml、14mmol)を加え、撹拌した。有機相を分離し、そして、pH値が、生成物の沈殿を引き起こす1〜2になるように、2NのHCl水溶液を加えた。混合物を20分間攪拌し、濾過し、濾過ケーキを真空下40℃で乾燥して、粗(IV).HCl(1.15g、HPLC純度:97.8%、2.2mmol、HPLC収率78.0%)を得た。
イミダゾール(1.4g、20.6mmol)、(Xa).HCl(2g、6.8mmol)、及び3−クロロ−4−(3−フルオロベンジルオキシ)アニリン((VII);1.8g、7.5mmol)のDMF(20ml、10P)溶液を、HPLC分析が反応完了を示すまで、攪拌しながら80±5℃(内部温度)で加熱した。0.5NのHCl水溶液(20ml)を70〜80℃でゆっくり加え、生成物が沈殿した。室温(25±5℃)まで冷却した後に、混合物を濾過し、水(20ml)で洗浄し、濾過ケーキを真空下60±5℃で16時間乾燥して、粗(IV).HCl(2.85g、HPLC純度89%、5.0mmol)を得た。
1H NMR(300MHz,d6−DMSO,1347−126−19): δ 7.47(d,J=3.6Hz,1H)、7.68(d,J=3.6Hz,1H)、7.77(d,J=8.7Hz,1H)、8.14(d,J=2.1Hz,1H)、8.28(dd,J=8.7Hz,J=2.1Hz,1H)、8.53(d,J=2.1Hz,1H)、9.64(s,1H)
Claims (27)
- ハロゲン化剤が塩素化剤である、請求項2のプロセス。
- 塩素化剤がSOCl2、POCl3、(COCl)2、PCl3、PCl5、及びCOCl2からなる群から選ばれる、請求項3のプロセス。
- 工程ii)をパラジウム系又は銅系触媒の存在下で行う、請求項2のプロセス。
- i)請求項1に記載のプロセスでラパチニブジトシレートを調製し、そして前記ラパチニブジトシレートを65〜80℃でジメチルスルホキシド(DMSO)に溶解する工程と、
ii)ラパチニブジトシレートが溶解した溶液に濾過操作を行う工程と、
iii)ラパチニブジトシレートの前記ジメチルスルホキシド(DMSO)溶液にアセトニトリル(MeCN)と水の混合物を65〜80℃で加える工程と、
iv)ラパチニブジトシレート一水和物が結晶化するように溶液を冷却する工程と、及び、
v)ラパチニブジトシレート一水和物結晶を単離する工程、
を含むラパチニブジトシレート一水和物結晶の調製プロセス。 - XがIである、請求項8のプロセス。
- 触媒が、遷移金属又は遷移金属塩と、ホスフィン配位子とを有する、請求項8のプロセス。
- 遷移金属又は遷移金属塩が、パラジウム又はパラジウム塩である、請求項11のプロセス。
- ホスフィン配位子が、P(t−Bu)3又はその塩誘導体である、請求項11のプロセス。
- 塩誘導体が[HP(t−Bu)3]BF4である、請求項13のプロセス。
- 塩基が、水酸化物、アルコキシド、金属炭酸塩、金属重炭酸塩、アミン、金属カルボン酸塩、又は金属リン酸塩である、請求項8のプロセス。
- 金属炭酸塩がNa2CO3である、請求項15のプロセス。
- 金属カルボン酸塩がAcOKである、請求項15のプロセス。
- 溶媒が、ジメチルスルホキシド(DMSO)、N,N−ジメチルホルムアミド(DMF)、N,N−ジメチルアセトアミド(DMAC)、N−メチルピロリドン(NMP)、アセトニトリル(MeCN)、又は1,4−ジオキサンと水の混合物である、請求項8のプロセス。
- 溶媒が、水とジメチルスルホキシド(DMSO)との混合物である、請求項18のプロセス。
- ジメチルスルホキシド(DMSO)のH2Oに対する体積比が、5:2である、請求項19のプロセス。
- 以下の工程を、粗反応生成物溶液中に溶解した式(IX)の化合物に対して行う、請求項8のプロセス。
i)溶解した式(IX)の化合物を、式(IX)の反応生成物が溶液に溶解したままになるような温度で、熱濾過する工程
ii)熱水を式(IX)の化合物を含有する熱濾液に加える工程
iii)溶液を冷却して式(IX)の化合物を結晶化させる工程
iv)式(IX)の化合物を単離する工程 - 反応を60〜95℃の間の温度で行う、請求項8のプロセス。
- 温度が80℃である、請求項22のプロセス。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31642510P | 2010-03-23 | 2010-03-23 | |
US61/316,425 | 2010-03-23 | ||
PCT/CN2011/000493 WO2011116634A1 (en) | 2010-03-23 | 2011-03-23 | Process and intermediates for preparing lapatinib |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013522327A JP2013522327A (ja) | 2013-06-13 |
JP5833626B2 true JP5833626B2 (ja) | 2015-12-16 |
Family
ID=44672462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013500311A Active JP5833626B2 (ja) | 2010-03-23 | 2011-03-23 | ラパチニブの調製プロセス及び中間体 |
Country Status (13)
Country | Link |
---|---|
US (1) | US8563719B2 (ja) |
EP (1) | EP2550269B1 (ja) |
JP (1) | JP5833626B2 (ja) |
KR (1) | KR101718578B1 (ja) |
CN (1) | CN102812019B (ja) |
AR (1) | AR088018A1 (ja) |
AU (1) | AU2011232219B2 (ja) |
CA (1) | CA2793742C (ja) |
ES (1) | ES2576871T3 (ja) |
IL (1) | IL222085A (ja) |
PT (1) | PT2550269E (ja) |
TW (1) | TWI453202B (ja) |
WO (1) | WO2011116634A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8916574B2 (en) | 2009-09-28 | 2014-12-23 | Qilu Pharmaceutical Co., Ltd. | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors |
MX2013007257A (es) | 2010-12-23 | 2013-10-01 | Apotex Pharmachem Inc | Un proceso para la preparación de lapatinib y su sal ditosilato. |
ITMI20110480A1 (it) * | 2011-03-25 | 2012-09-26 | F I S Fabbrica Italiana Sint P A | Procedimento per la preparazione di lapatinib e suoi sali |
CN102702179A (zh) * | 2012-06-13 | 2012-10-03 | 华南理工大学 | 4-(3-氯-4-甲氧基苯胺基)-6-(呋喃-2-基)喹唑啉类化合物或其药学上可接受的盐和制备方法与应用 |
CN102702116B (zh) * | 2012-06-13 | 2014-12-31 | 华南理工大学 | 4-(3-氯-4-甲氧基苯胺基)-6-(3-胺基苯基)喹唑啉类化合物或其药学上可接受的盐和制备方法与应用 |
CN105732596B (zh) * | 2012-11-19 | 2019-05-28 | 齐鲁制药有限公司 | N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法 |
CN103819461B (zh) * | 2012-11-19 | 2016-06-15 | 齐鲁制药有限公司 | N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法 |
US9024023B2 (en) | 2013-01-14 | 2015-05-05 | F.I.S.—Fabbrica Italiana Sintetici S.p.A. | Efficient process for the preparation of lapatinib and salts thereof by means of new intermediates |
WO2014170910A1 (en) | 2013-04-04 | 2014-10-23 | Natco Pharma Limited | Process for the preparation of lapatinib |
CN103242302B (zh) * | 2013-05-22 | 2015-08-05 | 苏州明锐医药科技有限公司 | 拉帕替尼的制备方法 |
CN104418845B (zh) * | 2013-09-04 | 2017-08-25 | 神隆医药(常熟)有限公司 | 制备拉帕替尼的方法和中间体 |
CN104513231A (zh) * | 2015-01-09 | 2015-04-15 | 安润医药科技(苏州)有限公司 | 拉帕替尼及其中间体的合成方法 |
EP3266773B1 (en) * | 2016-07-04 | 2018-04-11 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of lapatinib ditosylate monohydrate by means of an improved crystallization procedure |
CN106432206A (zh) * | 2016-08-30 | 2017-02-22 | 成都美睿科生物科技有限公司 | 一种用于合成拉帕替尼或其中间体5‑(4‑羟基喹唑啉)‑呋喃‑2‑甲醛的方法 |
WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
CN111153860B (zh) * | 2019-12-30 | 2021-06-29 | 广州六顺生物科技股份有限公司 | 一种喹唑啉类化合物的晶型及其制备方法 |
CN113321642A (zh) * | 2021-08-02 | 2021-08-31 | 北京鑫开元医药科技有限公司 | 一种喹唑啉类亚胺化合物及其应用和制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391874B1 (en) * | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
NZ522989A (en) | 2000-06-30 | 2005-06-24 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
AU2005203303B2 (en) | 2000-06-30 | 2008-04-24 | Glaxo Group Limited | Quinazoline ditosylate salt compounds |
JP4458746B2 (ja) * | 2001-01-16 | 2010-04-28 | グラクソ グループ リミテッド | 癌の治療方法 |
AU2004236239A1 (en) * | 2003-04-30 | 2004-11-18 | The Institutes For Pharmaceutical Discovery, Llc | Substituted heteroaryls as inhibitors of protein tyrosine phosphatases |
AU2005316238B2 (en) * | 2004-12-17 | 2009-05-07 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
WO2007113202A1 (en) * | 2006-03-31 | 2007-10-11 | Glaxo Group Limited | Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists |
US20090203718A1 (en) * | 2006-04-13 | 2009-08-13 | Smithkline Beecham (Cork) Ltd. | Cancer treatment method |
WO2008009078A2 (en) * | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
JP2010532366A (ja) * | 2007-06-29 | 2010-10-07 | サノフィ−アベンティス | 2−(3−{6−[2−(2,4−ジクロロフェニル)−エチルアミノ]−2−メトキシピリミジン−4−イル}−フェニル)−2−メチルプロピオン酸を製造する新しい方法 |
WO2009042613A1 (en) * | 2007-09-24 | 2009-04-02 | Tragara Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2] |
TW200920369A (en) * | 2007-10-26 | 2009-05-16 | Amira Pharmaceuticals Inc | 5-lipoxygenase activating protein (flap) inhibitor |
WO2009079541A1 (en) | 2007-12-18 | 2009-06-25 | Smithkline Beecham (Cork) Limited | Quinazoline ditosylate anhydrate forms |
US20100197915A1 (en) * | 2008-08-06 | 2010-08-05 | Leonid Metsger | Lapatinib intermediates |
-
2011
- 2011-03-23 TW TW100109970A patent/TWI453202B/zh active
- 2011-03-23 KR KR1020127024806A patent/KR101718578B1/ko active IP Right Grant
- 2011-03-23 EP EP11758744.4A patent/EP2550269B1/en active Active
- 2011-03-23 US US13/582,875 patent/US8563719B2/en active Active
- 2011-03-23 WO PCT/CN2011/000493 patent/WO2011116634A1/en active Application Filing
- 2011-03-23 AR ARP110100993A patent/AR088018A1/es unknown
- 2011-03-23 ES ES11758744.4T patent/ES2576871T3/es active Active
- 2011-03-23 CN CN201180015236.7A patent/CN102812019B/zh active Active
- 2011-03-23 PT PT117587444T patent/PT2550269E/pt unknown
- 2011-03-23 JP JP2013500311A patent/JP5833626B2/ja active Active
- 2011-03-23 CA CA2793742A patent/CA2793742C/en active Active
- 2011-03-23 AU AU2011232219A patent/AU2011232219B2/en not_active Ceased
-
2012
- 2012-09-23 IL IL222085A patent/IL222085A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
WO2011116634A1 (en) | 2011-09-29 |
EP2550269A4 (en) | 2013-08-21 |
AU2011232219A1 (en) | 2012-10-18 |
TW201141852A (en) | 2011-12-01 |
AU2011232219B2 (en) | 2016-02-04 |
JP2013522327A (ja) | 2013-06-13 |
IL222085A (en) | 2015-11-30 |
EP2550269A1 (en) | 2013-01-30 |
AU2011232219A9 (en) | 2015-09-24 |
CN102812019A (zh) | 2012-12-05 |
AR088018A1 (es) | 2014-05-07 |
CA2793742A1 (en) | 2011-09-29 |
PT2550269E (pt) | 2016-06-20 |
KR20130069552A (ko) | 2013-06-26 |
AU2011232219A2 (en) | 2013-01-31 |
US8563719B2 (en) | 2013-10-22 |
ES2576871T3 (es) | 2016-07-11 |
CA2793742C (en) | 2015-06-23 |
CN102812019B (zh) | 2015-12-16 |
KR101718578B1 (ko) | 2017-03-21 |
EP2550269B1 (en) | 2016-03-23 |
US20130005971A1 (en) | 2013-01-03 |
TWI453202B (zh) | 2014-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5833626B2 (ja) | ラパチニブの調製プロセス及び中間体 | |
TWI419867B (zh) | 用於製備整合酶抑制劑之方法及中間體 | |
JP2014516072A (ja) | アピキサバン製造方法 | |
JP7347852B2 (ja) | 重水素化大環状化合物の調製方法 | |
TWI295993B (en) | Mixed solvate of olanapine, method for preparing it and method for preparing form i of olanzapine therefrom | |
CN112851646A (zh) | 特戈拉赞的制备方法 | |
TWI541235B (zh) | 製備喹唑啉衍生物之方法 | |
US9359333B2 (en) | Efficient process for the preparation of Lapatinib and salts thereof by means of new intermediates | |
EP2754662B1 (en) | Efficient process for the preparation of Lapatinib and salts thereof by means of new intermediates | |
CA3044501A1 (en) | Chemical process for preparing imidazopyrrolidinone derivatives and intermediates thereof | |
US8093384B2 (en) | Processes for the preparation of alfuzosin | |
EP4073051B1 (en) | Process and intermediate for the preparation of oxetan-2-ylmethanamine | |
RU2450009C2 (ru) | Способ синтеза противораковых производных (поли)аминоалкиламиноацетамида эпиподофиллотоксина | |
WO2021162647A1 (en) | A novel process for preparation of pazopanib hydrochloride | |
EA043992B1 (ru) | Способ изготовления твердой формы ингибитора бромодомена bet | |
WO2017109027A1 (en) | Improved process for making crotonylaminopyridines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140320 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150428 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151020 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151029 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5833626 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |